Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1
1(33.3%)
Phase 2
1(33.3%)
Phase 1
1(33.3%)
3Total
Early Phase 1(1)
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04559685Early Phase 1Recruiting

Study of Sonodynamic Therapy in Participants with Recurrent High-Grade Glioma

Role: collaborator

NCT05123534Phase 2Suspended

A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

Role: lead

NCT05370508Phase 1Terminated

A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM

Role: lead

All 3 trials loaded